Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(146 productos)
- Bcr-Abl(102 productos)
- EGFR(572 productos)
- FAK(72 productos)
- FLT(92 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(245 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(79 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(268 productos)
Mostrar 6 subcategorías más
Se han encontrado 1431 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Apoptosis inducer 35
<p>Apoptosisinducer 35 (Compound 6) is a multi-target inhibitor that reduces the expression of EGFR, AKT, ERK, and P38-MAPKα. It suppresses the proliferation of cancer cells A549 and Jurkat, induces cell cycle arrest at the S phase, and triggers apoptosis (cell death).</p>Fórmula:C23H21ClN8O2S2Forma y color:SolidPeso molecular:541.048DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Forma y color:Odour SolidTephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Fórmula:C23H22O7Pureza:98%Forma y color:SolidPeso molecular:410.42JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OForma y color:SolidPeso molecular:407.4017-Hydroxyneolamellarin A
CAS:<p>7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.</p>Fórmula:C24H19NO5Forma y color:SolidPeso molecular:401.41PTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Fórmula:C49H51N11O8Pureza:98%Forma y color:SolidPeso molecular:922EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PForma y color:SolidPeso molecular:805.72SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Fórmula:C68H84N12O9Pureza:98%Forma y color:SolidPeso molecular:1213.47DB1113
CAS:<p>DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.</p>Fórmula:C59H68F3N13O6SForma y color:SolidPeso molecular:1144.31KIT/PDGFRA-IN-1
<p>KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.</p>Fórmula:C26H18F3N5O2Forma y color:SolidPeso molecular:489.449Abl Cytosolic Substrate
CAS:<p>Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).</p>Fórmula:C64H101N15O16Pureza:98%Forma y color:SolidPeso molecular:1336.58INCB-000928
CAS:<p>Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.</p>Fórmula:C30H38N4O3Pureza:98.93%Forma y color:SolidPeso molecular:502.65HIF-1 Signaling Pathway Compound Library
<p>A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；</p>Forma y color:Odour SolidTL13-12
CAS:<p>TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).</p>Fórmula:C45H53ClN10O10SPureza:98%Forma y color:SolidPeso molecular:961.49EGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Fórmula:C27H31N3O2Forma y color:SolidPeso molecular:429.24163cep-5214
CAS:<p>CEP-5214: Powerful pan VEGF-R tyrosine kinase inhibitor; IC50: 16nM (R1), 8nM (R2), 4nM (R3); effective in cells.</p>Fórmula:C28H28N2O3Forma y color:SolidPeso molecular:440.53EGFR-IN-151
<p>EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.</p>Forma y color:Odour SolidPROTAC EGFR degrader 4
CAS:<p>PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).</p>Fórmula:C55H70N12O4SForma y color:SolidPeso molecular:995.29MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Forma y color:SolidPeso molecular:993.47SI-2
CAS:<p>SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.</p>Fórmula:C15H15N5Pureza:98.4%Forma y color:SolidPeso molecular:265.31DD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Fórmula:C55H62N10O8Forma y color:SolidPeso molecular:991.163TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Forma y color:SolidPeso molecular:404.16485SNIPER(ABL)-015
<p>SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5</p>Fórmula:C58H70F3N9O9Pureza:98%Forma y color:SolidPeso molecular:1094.23PF15 TFA
<p>PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.</p>Fórmula:C46H50F3N13O8Pureza:98%Forma y color:SolidPeso molecular:969.97VEGFR-2-IN-64
<p>VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.</p>Fórmula:C72H123N9O6Forma y color:SolidPeso molecular:1210.8Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Fórmula:C36H35ClN6O8S3Pureza:98%Forma y color:SolidPeso molecular:811.34Cetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Forma y color:Odour LiquidHck-IN-2
<p>Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.</p>Fórmula:C36H35FN6O10Forma y color:SolidPeso molecular:730.696Si5-N14
CAS:<p>Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.</p>Fórmula:C78H160N6O5Si2Forma y color:SolidPeso molecular:1318.31PROTAC EGFR degrader 7
<p>Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.</p>Fórmula:C46H48N10O6Forma y color:SolidPeso molecular:836.94Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.77JAK/HDAC-IN-2
<p>JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.</p>Fórmula:C28H38N6O5SPureza:98%Forma y color:SolidPeso molecular:570.7Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Forma y color:LiquidEGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Fórmula:C20H17Cl2N3O3Forma y color:SolidPeso molecular:418.273VSLRGDTRG
CAS:<p>VSLRGDTRG is a synthetic peptide derived from the RGD motif in cadherin17 (CDH17) that binds to the α2β1 integrin, activating its signaling pathways. By promoting high-affinity conformational changes in β1 integrins through the RGD motif, VSLRGDTRG enhances cell adhesion and the phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. This peptide is useful for research on cancers expressing CDH17, such as colorectal and pancreatic cancer.</p>Fórmula:C38H69N15O14Forma y color:SolidPeso molecular:960.047MP-RM-1
<p>MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.</p>Forma y color:Odour LiquidEGFR/HER2/DHFR-IN-3
<p>EGFR/HER2/DHFR-IN-3 (compound 4c) serves as an efficacious dual inhibitor specifically targeting EGFR/HER2, exhibiting IC50 values of 0.138 μM for EGFR and 0.</p>Pureza:98%Forma y color:Odour SolidALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Fórmula:C29H39ClN7O2PForma y color:SolidPeso molecular:584.1BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Fórmula:C28H29FN6O2SForma y color:SolidPeso molecular:532.63EGFR/BRAFV600E-IN-4
<p>EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.</p>Fórmula:C22H16N4OSForma y color:SolidPeso molecular:384.45DSPE-PEG5000-A7R
<p>DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Forma y color:Odour SolidAD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Fórmula:C22H20F3N7OPureza:99.05%Forma y color:SoildPeso molecular:455.44AKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Fórmula:C17H14N6Pureza:99.88%Forma y color:SolidPeso molecular:302.33PST3.1a
CAS:<p>PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).</p>Fórmula:C32H33O6PForma y color:SolidPeso molecular:544.57EGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Fórmula:C22H17F3N4OPureza:98%Forma y color:SolidPeso molecular:410.39ALK protein ligand-1
CAS:<p>ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.</p>Fórmula:C24H29ClN6O3SForma y color:SolidPeso molecular:517.043Trastuzumab emtansine
CAS:<p>Trastuzumab emtansine is a HER2-targeted ADC for advanced breast cancer, combining trastuzumab with DM1 cytotoxicity.</p>Pureza:98%Forma y color:LiquidLyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Forma y color:SolidPeso molecular:915.028AXL/Angiokinase-IN-1
<p>AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.</p>Fórmula:C31H34ClN5O2Forma y color:SolidPeso molecular:544.09DSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Forma y color:Odour Solid
